--- title: "週三交易中，作為美國存託憑證交易的歐洲股票上漲" type: "News" locale: "zh-HK" url: "https://longbridge.com/zh-HK/news/273260837.md" description: "在美國交易的歐洲股票的美國存託憑證上漲，S&P Europe Select ADR Index 上漲了 0.49%，達到 1,744.86。顯著上漲的公司包括 BioNTech（+4.8%）和 Equinor（+2.6%），而下跌的公司包括 Novo Nordisk（-3.3%）和 Ascendis Pharma（-2.2%）。來自英國和愛爾蘭的 Silence Therapeutics 以 7.9% 的漲幅領漲，而 Mereo BioPharma Group 則下跌了 7.3%" datetime: "2026-01-21T16:16:00.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/273260837.md) - [en](https://longbridge.com/en/news/273260837.md) - [zh-HK](https://longbridge.com/zh-HK/news/273260837.md) --- # 週三交易中，作為美國存託憑證交易的歐洲股票上漲 11:16 AM EST, 01/21/2026 (MT Newswires) -- European equities traded in the US as American depositary receipts were tracking higher late Wednesday morning, rising 0.49% to 1,744.86 on the S&P Europe Select ADR Index. From continental Europe, the gainers were led by biotech firm BioNTech (BNTX) and petroleum refiner Equinor ( EQNR ) , which advanced 4.8% and 2.6% respectively. They were followed by biopharmaceutical company Grifols ( GRFS ) and semiconductor company Sequans Communications ( SQNS ) , which rose 2.1% and 1.7% respectively. The decliners from continental Europe were led by pharmaceutical companies Novo Nordisk ( NVO ) and Ascendis Pharma ( ASND ) , which fell 3.3% and 2.2% respectively. They were followed by internet advertising firm Criteo ( CRTO ) and biotech firm Evaxion ( EVAX ) , which lost 1.9% and 1.7% respectively. From the UK and Ireland, the gainers were led by pharmaceutical company Silence Therapeutics ( SLN ) and educational publisher Pearson (PSO), which increased 7.9% and 2.8% respectively. They were followed by software firm Endava ( DAVA ) and biopharmaceutical company NuCana ( NCNA ) , which were up 2.7% and 2.2% respectively. The decliners from the UK and Ireland were led by biopharmaceutical companies Mereo BioPharma Group ( MREO ) and Amarin ( AMRN ) , which dropped 7.3% and 2.7% respectively. They were followed by biopharmaceutical company Biodexa Pharmaceuticals ( BDRX ) and pharmaceutical company AstraZeneca ( AZN ) , which were down 1.8% and 0.6% respectively. MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited. ### 相關股票 - [IHI.US](https://longbridge.com/zh-HK/quote/IHI.US.md) - [BIB.US](https://longbridge.com/zh-HK/quote/BIB.US.md) - [SPEU.US](https://longbridge.com/zh-HK/quote/SPEU.US.md) - [FBT.US](https://longbridge.com/zh-HK/quote/FBT.US.md) - [BBH.US](https://longbridge.com/zh-HK/quote/BBH.US.md) - [SBIO.US](https://longbridge.com/zh-HK/quote/SBIO.US.md) - [SSEHF.US](https://longbridge.com/zh-HK/quote/SSEHF.US.md) - [IXJ.US](https://longbridge.com/zh-HK/quote/IXJ.US.md) - [IBB.US](https://longbridge.com/zh-HK/quote/IBB.US.md) - [XLV.US](https://longbridge.com/zh-HK/quote/XLV.US.md) - [VHT.US](https://longbridge.com/zh-HK/quote/VHT.US.md) - [IHE.US](https://longbridge.com/zh-HK/quote/IHE.US.md) - [BNTX.US](https://longbridge.com/zh-HK/quote/BNTX.US.md) - [NVO.US](https://longbridge.com/zh-HK/quote/NVO.US.md) - [XBI.US](https://longbridge.com/zh-HK/quote/XBI.US.md) - [ASND.US](https://longbridge.com/zh-HK/quote/ASND.US.md) - [IBBQ.US](https://longbridge.com/zh-HK/quote/IBBQ.US.md) - [ARKG.US](https://longbridge.com/zh-HK/quote/ARKG.US.md) - [EQNR.US](https://longbridge.com/zh-HK/quote/EQNR.US.md) - [SLN.US](https://longbridge.com/zh-HK/quote/SLN.US.md) - [MREO.US](https://longbridge.com/zh-HK/quote/MREO.US.md) - [STOHF.US](https://longbridge.com/zh-HK/quote/STOHF.US.md) - [PBE.US](https://longbridge.com/zh-HK/quote/PBE.US.md) - [XHE.US](https://longbridge.com/zh-HK/quote/XHE.US.md) ## 相關資訊與研究 - [鉅亨速報 - Factset 最新調查：Ascendis Pharma A/S - ADR(ASND-US) EPS 預估上修至 13.67 元，預估目標價為 250.22 元](https://longbridge.com/zh-HK/news/286911202.md) - [鉅亨速報 - Factset 最新調查：Ascendis Pharma A/S - ADR(ASND-US) EPS 預估上修至 13.45 元，預估目標價為 249.35 元](https://longbridge.com/zh-HK/news/286592883.md) - [鉅亨速報 - Factset 最新調查：Roivant Sciences LtdROIV-US 的目標價調升至 38 元，幅度約 8.57%](https://longbridge.com/zh-HK/news/287126179.md) - [川普投資組合神操作？Medicare 政策翻盤前 精準大買聯合健康](https://longbridge.com/zh-HK/news/287039034.md) - [復宏漢霖：注射用 HLX43 用於治療晚期非小細胞肺癌的國際多中心 2 期臨牀研究完成首例患者給藥](https://longbridge.com/zh-HK/news/287195179.md)